PGT-M (formerly PGD) is considered medically necessary when all policy criteria are met: the test’s technical and clinical performance is supported by peer‑reviewed literature; the indication is for a defined single‑gene or parental structural rearrangement risk (autosomal dominant with ≥1 parent carrier, autosomal recessive with both parents carriers, X‑linked with ≥1 parent carrier, or embryo at risk because a parent carries a balanced/unbalanced rearrangement); results will directly change management; the PGT‑M procedure will eliminate the need for subsequent invasive prenatal diagnosis (CVS or amniocentesis); a specific mutation (or set of mutations) has been identified that reliably identifies the disease; and the condition is associated with clinically significant morbidity or disability. (Coverage requirements summarized from policy criteria.)

PGT‑M is not medically necessary when used for non‑medical sex selection. The policy also states that using PGT‑M/PGD to evaluate fetal chromosomal abnormalities is considered investigational because PGT‑M is less accurate than cytogenetic analysis of CVS or amniocentesis. For single‑cell PCR‑based PGT‑M, intracytoplasmic sperm injection (ICSI) is recommended to avoid contamination; the embryo biopsy procedure itself is considered medically necessary only when the PGT‑M criteria are satisfied. (See policy notes on technique and IVF coordination.)

Cleavage‑stage PGS using FISH (day‑3 blastomere biopsy with FISH‑based analysis) has not been shown to improve live‑birth rates and may be detrimental. Randomized trials and systematic reviews concluded that PGS as historically performed does not increase live births in women of advanced maternal age, previous implantation failure, or recurrent pregnancy loss, and evidence does not support routine use of FISH‑based cleavage‑stage PGS to improve IVF outcomes.

Professional society reviews and meta‑analyses cited in the policy indicate that day‑3 blastomere biopsy with FISH decreases the chance of live birth and therefore is not recommended as routine care for advanced maternal age or prior implantation failure. Where new methods (blastocyst biopsy with comprehensive chromosome testing) are evaluated, the policy emphasizes the need for rigorous evidence before adoption.

The policy concludes that PGT‑A performed with first‑generation cleavage‑stage FISH is probably harmful and is not supported by the evidence. Meta‑analyses of randomized trials that used cleavage‑stage biopsy with FISH reported lower live‑birth and ongoing pregnancy rates compared with standard IVF, leading to the assessment that this modality is detrimental rather than beneficial.

Because of technical limitations (testing a single blastomere, mosaicism, and FISH’s limited chromosome coverage), first‑generation FISH‑based PGT‑A is specifically identified as an approach that should not be used routinely.

The policy states that use of FISH for genetic analysis in PGT‑A is probably harmful and should not be performed routinely. Systematic reviews and randomized trials report reductions in pregnancy and live‑birth outcomes with FISH‑based approaches, and technical drawbacks (including mosaicism and limitations in probe coverage) underlie these unfavorable results.

Newer forms of PGT‑A (e.g., blastocyst‑stage biopsy with genome‑wide methods) remain unproven for routine use and, as discussed in the policy, should be evaluated in controlled study settings before broad clinical adoption.

This Clinical Policy Bulletin provides a general description of plan benefits and evidence‑based coverage positions; it does not constitute a contract. Specific plan exclusions, coverage limits, and benefit determinations are governed by the member’s benefit plan documents and applicable contract provisions rather than the bulletin itself.

Readers should also note that certain laboratory‑specific assays are discussed as investigational in the policy (see investigational list) and plan‑level applicability may vary according to benefit design and adjudication rules.

PGT‑A (formerly PGS), invasive prenatal screening for variants of uncertain significance (VUS), and PGT‑M performed to evaluate a VUS or using multigene panels at the time of PGT‑M are considered investigational or not medically necessary. The policy lists PGT‑A/PGS and use of PGT for VUS detection or routine multigene panels at embryo testing among interventions that lack sufficient evidence of clinical utility and may be denied coverage.

Specific named commercial assays (examples cited elsewhere in the policy) are evaluated on the basis of published peer‑reviewed performance data; assays without such evidence are noted as not supported.

Randomized trial data and evidence syntheses indicate that PGS using day‑3 blastomere biopsy with FISH decreases live‑birth rates and therefore is not recommended for women of advanced maternal age or those with prior implantation failure. The policy recommends against routine use of day‑3 cleavage‑stage biopsy with FISH for these higher‑risk groups based on trials showing worse outcomes compared with standard IVF.

Where alternative biopsy timing (blastocyst-stage) and comprehensive chromosome testing have been studied, the evidence is limited and inconclusive, and the policy cautions that such newer approaches should be validated in randomized settings before routine clinical use.

Overall, routine use of PGT‑A as currently performed is unsupported by high‑quality evidence and is considered not appropriate for broad clinical application. Meta‑analyses and Cochrane‑style reviews found insufficient evidence that PGT‑A increases cumulative live‑birth rates or live‑birth rates after the first embryo transfer, and in some analyses PGT‑A was associated with reductions in ongoing pregnancy and clinical pregnancy rates.

The policy therefore characterizes routine PGT‑A as lacking established clinical utility and notes that PGT‑A using FISH is probably harmful.

Evidence is insufficient to support routine clinical use of PGT‑A: randomized trials, systematic reviews, and meta‑analyses demonstrate low‑to‑moderate quality evidence with inconsistent findings and potential harm with some modalities. The policy emphasizes that clinical utility of PGT‑A remains unestablished, that false‑positive/false‑negative and mosaic results are possible, and that traditional diagnostic testing should still be offered to patients who have had PGT‑A.

Given these limitations, PGT‑A for routine IVF or for broad patient populations is considered investigational pending higher‑quality evidence from randomized trials showing net clinical benefit.

The policy lists as not covered interventions including: PGT‑A/PGS generally; testing intended to detect variants of uncertain significance (VUS); use of multigene panels at the time of PGT‑M; HLA determination via PGT for donor‑suitability purposes; and specific commercial assays for which peer‑reviewed evidence of technical and clinical performance is lacking.

These exclusions reflect the policy’s stance that such uses are experimental/investigational or lack demonstrated clinical utility and therefore are not routinely reimbursed.

Routine FISH‑based cleavage‑stage PGS is identified as not supported to improve live‑birth rates and may be ineffective or potentially harmful. The policy references randomized trials and meta‑analyses showing lower ongoing pregnancy and live‑birth rates with cleavage‑stage FISH‑based PGS compared with standard IVF, and therefore excludes routine coverage for this modality.

The policy recommends that newer array‑based or blastocyst‑stage approaches be studied rigorously before routine adoption, and that FISH‑based cleavage‑stage PGS should not be offered as standard care.

Routine PGT‑A as currently performed—particularly FISH‑based cleavage‑stage methods—is unsupported by sufficient good‑quality evidence and may be excluded from routine coverage. Meta‑analytic data cited in the policy indicate possible reductions in clinical and ongoing pregnancies with PGT‑A in some trials, underpinning the not‑covered stance for routine use.

The policy stresses that until robust evidence demonstrates improved cumulative live‑birth outcomes, routine PGT‑A will not be considered a covered, standard addition to IVF.

The policy explicitly states that offering PGT‑A as a routine addition to IVF is not supported by sufficient evidence; first‑generation (FISH‑based) PGT‑A is described as probably harmful. As a result, routine incorporation of PGT‑A into IVF cycles is not covered and may be denied when submitted as a standard, non‑research intervention.

Newer PGT‑A approaches (blastocyst biopsy with genome‑wide testing) remain investigational and, per the policy, should be offered only under study conditions with informed consent.

PGT‑M (preimplantation genetic testing for monogenic disorders) detects specific single‑gene disorders by molecular analysis of single embryonic cells and is medically necessary when the policy’s strict criteria are satisfied. The procedure is intended to identify embryos unaffected by a known familial mutation so that affected embryos are not transferred, thereby eliminating the need for later invasive prenatal diagnosis when criteria are met.

For conditions such as cystic fibrosis or fragile X (with parental premutation defined in the policy as >55 triplet repeats for Fragile X carrier status), PGT‑M is an established clinical application when parental carrier status and the causative mutation(s) have been documented.

The policy does not list additional standalone eligibility requirements in separate sections beyond the PGT‑M criteria themselves. Coverage for PGT‑M is tied to demonstration of parental carrier status or documented familial mutation(s) and to meeting the listed medical‑necessity criteria; other eligibility nodes (such as age or prior treatments) are not specified as independent top‑level requirements in this excerpt.

For invasive prenatal diagnostic procedures (CVS, amniocentesis, PUBS) coverage is described by clinical indications (e.g., fetal ultrasound abnormality, increased nuchal translucency >3.5 mm, or familial chromosomal rearrangement) rather than by separate eligibility checklists.

The policy’s eligibility expectations are embodied in the PGT‑M medical necessity criteria: identification of a specific mutation or parental carrier status is required, and the test must be expected to change management and obviate invasive prenatal diagnosis. No additional eligibility elements (such as explicit age cutoffs or prior authorization prerequisites) are defined as separate top‑level nodes in this excerpt.

Providers should ensure documentation demonstrates how the case meets each PGT‑M criterion before submission for coverage adjudication.

This section does not specify extra eligibility criteria beyond the core policy statements. Instead, the policy focuses on clinical indications and evidence‑based justification for PGT‑M and invasive prenatal diagnostic testing, leaving plan‑specific benefit limits and any administrative eligibility rules to the member’s benefit documents.

When considering PGT‑A (investigational/not covered for routine use) or other investigational applications, providers should be aware that eligibility for coverage is unlikely absent participation in approved research or explicit plan provisions allowing such services.

The policy references parental carrier identification as the primary prerequisite for PGT‑M: for autosomal recessive disorders both parents must be carriers; for autosomal dominant and X‑linked disorders at least one parent must be a carrier. Identification of a known familial structural rearrangement (translocation) is likewise required before offering PGD for structural rearrangements.

These family‑history and diagnostic prerequisites are the operative eligibility requirements for PGT‑M coverage in this policy excerpt.

The policy does not enumerate additional administrative eligibility nodes in this excerpt. It emphasizes that PGT‑A, multigene panels at time of PGT‑M, and testing for VUS are investigational and not covered, reinforcing that eligibility for those services is not present under routine coverage.

Clinicians should use the policy’s clinical criteria (documented mutation/carrier status and expected change in management) as the basis for determining whether the member meets coverage conditions for PGT‑M.

No separate top‑level eligibility nodes (e.g., specific age or prior trial requirements) are provided in this excerpt beyond the PGT‑M clinical criteria and the listed clinical indications for invasive prenatal diagnosis. The policy ties coverage decisions to clinical evidence and individualized demonstration that PGT‑M will change management and eliminate invasive testing.

Providers should document parental testing and mutation identification as part of eligibility assessment for PGT‑M claims.

The policy does not specify additional eligibility components in this fragment; rather, coverage is decisioned on meeting the explicit medical‑necessity criteria and the presence of documented familial genetic findings. Newer PGT‑A approaches remain investigational and are not covered routinely, independent of additional eligibility features.

Where investigational procedures are proposed, the policy suggests they may be appropriate only within properly conducted research protocols with informed consent.

Eligibility for PGT‑M coverage is predicated on demonstration of known parental carrier status or a specific familial mutation and meeting each of the medical‑necessity criteria (test performance evidence; impact on management; elimination of invasive testing; identification of the causative mutation; and association with significant morbidity). The policy does not enumerate additional administrative eligibility nodes in this excerpt.

Providers should ensure the clinical record documents the mutation(s) identified in the family and explains how PGT‑M results will directly alter management to support coverage.

The policy cites a broad literature base including multiple randomized trials, meta‑analyses, and systematic reviews assessing PGT‑A/PGS and PGT‑M. For PGT‑A, Cochrane‑style reviews and meta‑analyses (summarized across 13 trials/2,794 women in some reviews and 5 RCTs in specific analyses) report low‑to‑moderate quality evidence with inconsistent results and possible reductions in ongoing pregnancy or live‑birth rates for some modalities.

Randomized trials and meta‑analyses (e.g., Mastenbroek et al., Checa et al.) underpin the policy’s conclusions that FISH‑based cleavage‑stage PGS reduced live births in some studies and that evidence for newer genome‑wide PGT‑A approaches is currently insufficient. The references list in the policy includes 70+ citations supporting these evidence summaries.